|
會議將同時進行
|
|
Preclinical Development 概要
|
|
[
概要 |
展銷前置會 |
1日目 |
2日目 |
3日目 |
Catalog(PDF) ]
|
|
第4回 臨床前開發 - 臨床安全性的預測改善方法
2008年3月26∼28日
開幕議程:專題演講（藥劑安全性動向之共同議程）
毒性試驗和預測的最新動向（藥劑安全性動向之共同議程）
案例學習：臨床前開發之成功和失敗（藥劑安全性動向之共同議程）
毒性經路 （臨床前開發、藥劑安全性動向、及癌的分子標靶之共同議程）
- 生物醫藥品的毒性試驗的適切模型：從Tegenero所得之教訓（藥劑安全性動向之共同議程）
- 用於內部的決定和規範認可的雙方之影像檢測的選定(轉譯醫學之共同議程)
|
|
Keynote Session
|
 |
Improving R&D Productivity Through Better Preclinical
Decision Making and Science
B. Michael Silber, Ph.D., Senior Vice President and Head Safety
& Technical
Sciences (Preclinical Development), Roche Pharmaceuticals, LLC
|
 |
Toxicity Testing in the 21st Century: Opportunities for
Pharmaceutical Risk Assessment
Daniel Krewski, Ph.D., MHA, Professor and Director,
McLaughlin Centre for Population Health Risk Assessment,
University of Ottawa
|
|
|
Highlighted Presentations
|
 |
From Publication to Practice: Interlaboratory Validation of Microarray and QPCR-based Signatures for Predicting Carcinogenicity in the Rat
Mark Fielden, Ph.D., DABT, Discovery and Investigative Safety, Non-Clinical Drug Safety, Roche Palo Alto LLC
|
 |
Mechanistic Cardiac Modeling: Concepts and Utility in
Drug Development
Anna Georgieva, Ph.D., Associate Director, Modeling & Simulation,
and Ruben Bibas, Ph.D., Biology Modeler, Modeling &
Simulation, Novartis Inc.
|
 |
Challenges of Doxercalciferol, a Prodrug of a Potent
Vitamin D Hormone
Joyce Knutson, Ph.D., Senior Director of Research, Bone Care
International
|
 |
Defining and Finding Relevant Animal Models:
The Evolution of 𣫮elevant�EDuring Development
Nancy Wehner, Ph.D., Senior Director, Non-clinical Safety
Evaluation, Elan Pharmaceuticals
|
 |
Predicting the Undesirable Pharmacodynamic Effects of
Small Molecules on Physiological Function: From the Brain to the Heart
Vivek Kadambi, Ph.D., Director of Drug Safety Evaluation,
Millennium Pharmaceuticals, Inc.
|
 |
Predicting Cardiac Toxicity with Adjuant Trastuzumab Therapy
Ellie Guardino, M.D., Ph.D., Assistant Professor of Medicine,
Breast Oncology, Stanford University
|
 |
Imaging Biomarkers in Early Clinical Development of
Novel Therapeutic Agents
Jeffrey L. Evelhoch, Ph.D., Executive Director, Medical Sciences,
Imaging, Amgen Inc.
|
|
|
Session:
|
-
Advances in Toxicity Testing and Prediction
-
Case Studies: Successes and Failures in Preclinical Development
-
Toxicity Pathways
-
Finding the Relevant Model for Toxicity Testing
-
Choosing an Imaging Modality
|
|
|
|
Hot Topics This Year:
|
-
Interlaboratory Validation of Signatures for Predicting
Carcinogenicity
-
Mechanistic Cardiac Modeling and Utility in Drug
Development
-
Defining and Finding Relevant Animal Models
-
Advances in Liver Toxicity Testing
-
Predicting Cytokine Storms from in Vitro Cell Based Models
-
Translating Safety from Animals to FIH Studies of
Biologics
|
|
|
|
Japanese
Korean
English